Abstract
Cellular therapies have demonstrated limited efficacy thus far in acute myeloid leukemia (AML). A recent study shows that mTOR complex 1 activation downregulated CXCR4 reducing marrow infiltration of EpCAM-targeting chimeric antigen receptor (CAR) T-cells in AML. Abrogating mTOR signaling by cotreatment with mTOR inhibitors during IL2-mediated ex vivo expansion upregulated CXCR4 and bolstered bone marrow migration and AML elimination by CAR T-cells.
Original language | English (US) |
---|---|
Pages (from-to) | 5739-5741 |
Number of pages | 3 |
Journal | Clinical Cancer Research |
Volume | 27 |
Issue number | 21 |
DOIs | |
State | Published - Nov 15 2021 |
ASJC Scopus subject areas
- Oncology
- Cancer Research